|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 47/54 | |
| A61P 5/00 |
| (11) | Patento numeris | 2525834 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11705470.0 |
| Europos patento paraiškos padavimo data | 2011-01-24 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-11-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-07-17 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/050923 |
| Data | 2011-01-24 |
| (87) | Numeris | WO 2011/089255 |
| Data | 2011-07-28 |
| (30) | Numeris | Data | Šalis |
| 297305 P | 2010-01-22 | US | |
| 10151405 | 2010-01-22 | EP |
| (72) |
BEHRENS, Carsten, DK
JOHANSEN, Nils Langeland, DK
ANDERSEN, Henrik Sune, DK
N RSKOV-LAURITSEN, Leif, DK
BUCHARDT, Jens, DK
|
| (73) |
Novo Nordisk Health Care AG,
Thurgauerstrasse 36/38 8050 Zürich,
CH
|
| (54) | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY |
| GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY |